건선의 치료 접근법에 대한 고찰 및 제언

키워드

참고문헌 (100)

1. The Society of Korean Dermatology, "Textbook of Dermatology", pp.299~ (2015), Daehan Med
2. Kamiya K, "Risk Factors for the Development of Psoriasis", Int J Mol Sci, 20(18), pp.4347~ (2019)
3. 이진용, "Prevalence of Psoriasis in Korea: A Population-Based Epidemiological Study Using the Korean National Health Insurance Database", Annals of Dermatology, 29(6), pp.761~767 (2017), 대한피부과학회
4. Greb JE, "Psoriasis", Nat Rev Dis Primers, 2, pp.16082~ (2016)
5. 김봉현, "건선 치료용 한약제제에 대한 임상시험 가이드라인 설명 및 제언", 한방안이비인후피부과학회지, 31(2), pp.40~59 (2018), 대한한방안이비인후피부과학회[DOI]
6. Canavese M, "Vascular endothelial growth factor (VEGF)in the pathogenesis of psoriasis—a possible target for novel therapies?", J Dermatol Sci, 58(3), pp.171~176 (2010)
7. Luan L, "Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-α treatment in psoriasis", Int Immunopharmacol, 29(2), pp.278~284 (2015)
8. Lynde CW, "Interleukin 17A : toward a new understanding of psoriasis pathogenesis", J Am Acad Dermatol, 71(1), pp.141~150 (2014)
9. Lizzul PF, "Differential expression of phosphorylated NF-κB", RelA in normal and psoriatic epidermis and downregulation of NF-κB in response to treatment with etanercept, 2005, pp.124(6), 1275~1283
10. Lin Y, "Comparison of indirubin concentrations in indigo naturalis ointment for psoriasis treatment : a randomized, double-blind, dosage-controlled trial", British Journal of Dermatology, 178(1), pp.124~131 (2018)
11. Yan Y, "Exploratory clinical trial to evaluate the efficacy of a topical traditional Chinese herbal medicine in psoriasis vulgaris", Evidence-Based Complementary and Alternative Medicine, 2015, pp.719641~ (2015)
12. Lin Y, "A Chinese herb, indigo naturalis, extracted in oil(Lindioil)used topically to treat psoriatic nails : a randomized clinical trial", Jama Dermatology, 151(6), pp.672~674 (2015)
13. Cheng H, "Clinical efficacy and IL-17targeting mechanism of Indigo naturalis as a topical agent in moderate psoriasis", BMC complementary and alternative medicine, 17(1), pp.1~11 (2017)
14. Wu M, "The immunoregulatory effects of traditional Chinese medicine on psoriasis via its action on interleukin : advances and considerations", The American journal of Chinese medicine, 46(04), pp.739~750 (2018)
15. Wang D, "PDTCM : a systems pharmacology platform of traditional Chinese medicine for psoriasis", Annals of medicine, 49(8), pp.652~660 (2017)
16. Lu C, "Herbal components of a novel formula PSORI-CM02 interdependently suppress allograft rejection and induce CD8+ CD122+PD-1+ regulatory T cells", Frontiers in pharmacology, 9, pp.88~ (2018)
17. Sun W, "‘Psoriasis 1’reduces psoriasis‑like skin inflammation by inhibiting the VDR‑mediated nuclear NF‑κB and STAT signaling pathways", Molecular medicine reports, 18(3), pp.2733~2743 (2018)
18. Eppinga H, "The microbiome and psoriatic arthritis", Curr Rheumatol Rep, 16(3), pp.407~ (2014)
19. Takeshita J, "Psoriasis and comorbid diseases : Epidemiology", J Am Acad Dermatol, 76(3), pp.377~390 (2017)
20. Huang BL, "Skin manifestations of inflammatory bowel disease", Front Physiol, 3, pp.13~ (2012)
21. Cohen AD, "Psoriasis associated with ulcerative colitis and Crohn's disease", J Eur Acad Dermatol Venereol, 23(5), pp.561~565 (2009)
22. Pietrzak D, "Digestive system in psoriasis : an update", Arch Dermatol Res, 309(9), pp.679~693 (2017)
23. van Schaik FD, "Serological markers predict inflammatory bowel disease years before the diagnosis", Gut, 62(5), pp.683~688 (2013)
24. Li WQ, "Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women", Ann Rheum Dis, 72(7), pp.1200~1205 (2013)
25. Juzlova K, "Gastrointestinal comorbidities in patients with psoriasis in the Czech Republic : The results of 189 patients with psoriasis and 378 controls", Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 160(1), pp.100~105 (2016)
26. Scarpa R, "Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms", J Rheumatol, 27(5), pp.1241~1246 (2000)
27. Michaelsson G, "The skin and the gut in psoriasis : the number of mast cells and CD3+ lymphocytes is increased in non-involved skin and correlated to the number of intraepithelial lymphocytes and mast cells in the duodenum", Acta Derm Venereol, 77(5), pp.343~346 (1997)
28. Sikora M, "Intestinal barrier integrity in patients with plaque psoriasis", J Dermatol, 45(12), pp.1468~1470 (2018)
29. Atkins D, "Mucosal immunology, eosinophilic esophagitis, and other intestinal inflammatory diseases", J Allergy Clin Immunol., 125(2 Suppl 2), pp.S255~S261 (2010)
30. Mowat AM, "Regional specialization within the intestinal immune system", Nat Rev Immunol, 14(10), pp.667~685 (2014)
31. Pietrzak A, "Lipid disturbances in psoriasis : an update", Mediators Inflamm, 2010, pp.535612~ (2010)
32. Singh S, "An update on psoriasis and metabolic syndrome : A meta-analysis of observational studies", PLoS One, 12(7), pp.e0181039~ (2017)
33. Langan SM, "Prevalence of metabolic syndrome in patients with psoriasis : a population-based study in the United Kingdom", J Invest Dermatol, 132(3 Pt 1), pp.556~562 (2012)
34. Itani S, "High prevalence of metabolic syndrome in patients with psoriasis in Lebanon : a prospective study", Int J Dermatol, 55(4), pp.390~395 (2016)
35. Parodi A, "Metabolic syndrome prevalence in psoriasis : a cross-sectional study in the Italian population", Am J Clin Dermatol, 15(4), pp.371~377 (2014)
36. Karoli R, "A study of cardio-metabolic risk profile in patients with psoriasis", J Assoc Physicians India, 61(11), pp.798~803 (2013)
37. Sommer DM, "Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis", Arch Dermatol Res, 298(7), pp.321~328 (2006)
38. Al-Mutairi N, "The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy : a randomized controlled prospective trial", Expert Opin Biol Ther, 14(6), pp.749~756 (2014)
39. Snekvik I, "Metabolic syndrome and risk of incident psoriasis : prospective data from the HUNT Study, Norway", Br J Dermatol, 180(1), pp.94~99 (2019)
40. Akhyani M, "The lipid profile in psoriasis : a controlled study", J Eur Acad Dermatol Venereol, 21(10), pp.1330~1332 (2007)
41. Amin T, "Atherosclerotic risk in psoriasis", Journal of Pan Arab League of Dermatologists, 16(2), pp.39~45 (2005)
42. Bajaj DR, "Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad", J Pak Med Assoc, 59(8), pp.512~ (2009)
43. Cohen AD, "Association between psoriasis and the metabolic syndrome. A cross-sectional study", Dermatology, 216(2), pp.152~155 (2008)
44. Coimbra S, "Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease", J Dermatol Sci, 55(3), pp.202~204 (2009)
45. Gisondi P, "Prevalence of metabolic syndrome in patients with psoriasis : a hospital-based case-control study", Br J Dermatol, 157(1), pp.68~73 (2007)
46. Javidi Z, "Serum lipids abnormalities and psoriasis", Indian J Dermatol, 52(2), pp.89~ (2007)
47. Kural BV, "Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant–antioxidant system in patients with psoriasis", Clinica chimica acta, 328(1-2), pp.71~82 (2003)
48. Mallbris L, "Psoriasis is associated with lipid abnormalities at the onset of skin disease", J Am Acad Dermatol, 54(4), pp.614~621 (2006)
49. Örem A, "The significance of autoantibodies against oxidatively modified low-density lipoprotein(LDL)in patients with psoriasis", Clinica chimica acta, 284(1), pp.81~88 (1999)
50. activity, serum lipid profile and peripheral blood dendritic cell populations in normolipidemic males with psoriasis, "J Mol Catal", 2006, 144~154
51. SuleymanPiskin, "Serum Lipid Levels in Psoriasis", Yonsei Medical Journal, 44(1), pp.24~26 (2003), 연세대학교의과대학
52. Rocha-Pereira P, "Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease", Clin Chim Acta, 303(1-2), pp.33~39 (2001)
53. Tekin NS, "Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients", Mediators Inflamm, 2007, pp.78454~ (2007)
54. Hadas E, "Impact of phototherapy on selected lipid profile indices in psoriatic patients allowing", Postepy Dermatol Alergol, 24(5), pp.215~ (2007)
55. Reynoso-von Drateln C, "Lipid profile, insulin secretion, and insulin sensitivity in psoriasis", J Am Acad Dermatol, 48(6), pp.882~885 (2003)
56. Abedini R, "Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease", Clin Exp Dermatol, 40(7), pp.722~727 (2015)
57. Gisondi P, "Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis", J Hepatol, 51(4), pp.758~764 (2009)
58. van der Voort EA, "Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older : Results from a population-based study", J Am Acad Dermatol, 70(3), pp.517~524 (2014)
59. Koppe SW, "Obesity and the liver : nonalcoholic fatty liver disease", Transl Res, 164(4), pp.312~322 (2014)
60. Carrascosa JM, "Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal : results of the Biobadaderm Registry", J Eur Acad Dermatol Venereol, 28(7), pp.907~914 (2014)
61. Boehncke WH, "The ‘psoriatic march’ : a concept of how severe psoriasis may drive cardiovascular comorbidity", Exp Dermatol, 20(4), pp.303~307 (2011)
62. Takeshita J, "Psoriasis and comorbid diseases : Implications for management", J Am Acad Dermatol, 76(3), pp.393~403 (2017)
63. Gelfand JM, "Metabolic syndrome in patients with psoriatic disease", J Rheumatol Suppl, 89, pp.24~28 (2012)
64. Ganzetti G, "Non-alcoholic fatty liver disease and psoriasis : So far, so near", World J Hepatol, 7(3), pp.315~326 (2015)
65. Grozdev I, "Psoriasis as a systemic disease", Clin Dermatol, 32(3), pp.343~350 (2014)
66. Frieder J, "Psoriasis and cardiovascular disorders", G Ital Dermatol Venereol, 151(6), pp.678~693 (2016)
67. Arican O, "Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity", Mediators Inflamm, 2005(5), pp.273~279 (2005)
68. 홍성인, "HepG2 cell에서 유리지방산 유발 지방독성에 대한 生肝健脾湯과 일부 조성 한약물의 효과", 대한한방내과학회지, 34(1), pp.14~30 (2013), 대한한방내과학회
69. Choi ES, "A Case Report of Adolescent Nonalcoholic Fatty Liver Disease (NAFLD)with Severe Obesity", J Int Korean Med, pp.89~95 (2015)
70. Sin SM, "Saenggangeonbi-tang's effest on metabolic syndrome", J Int Korean Med., pp.65~70 (2008)
71. Kang KR, "A Male Nonalcoholic Steatohepatitis (NASH) Patient Diagnosed with Moderate Fibrosis using Fibroscan-a Case Report", J Int Korean Med, pp.120~126 (2015)
72. Swindell WR, "Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis", PLoS One, 6(4), pp.e18266~ (2011)
73. Nakajima K, "Barrier abnormality due to ceramide deficiency leads to psoriasiform inflammation in a mouse model", J Invest Dermatol, 133(11), pp.2555~2565 (2013)
74. Ye L, "Abnormal epidermal barrier recovery in uninvolved skin supports the notion of an epidermal pathogenesis of psoriasis", J Invest Dermatol, 134(11), pp.2843~ (2014)
75. Kyung-Kook Hong, "A Study on Altered Expression of Serine Palmitoyltransferase andCeramidase in Psoriatic Skin Lesion", Journal of Korean Medical Science, 22(5), pp.862~867 (2007), 대한의학회
76. Motta S, "Abnormality of water barrier function in psoriasis. Role of ceramide fractions", Arch Dermatol, 130(4), pp.452~456 (1994)
77. Ansidei V, "Phospholipid involvement in psoriatic epidermis", Ital J Biochem, 30(1), pp.40~45 (1981)
78. Khyshiktuev BS, "Alterations in the parameters of lipid metabolism in different biological objects in psoriatic patients during exacerbation and remission", Vestn Dermatol Venerol, 6, pp.40~43 (2005)
79. Khyshiktuev BS, "Variability of quantitative changes in short-chain fatty acids in serum and epidermis in psoriasis", Klin Lab Diagn, (8), pp.22~24 (2008)
80. Maxfield FR, "Role of cholesterol and lipid organization in disease", Nature, 438(7068), pp.612~621 (2005)
81. Melton JL, "Effects of essential fatty acid deficiency on epidermal O-acylsphingolipids and transepidermal water loss in young pigs", BBA-Mol Cell Biol L, 921(2), pp.191~197 (1987)
82. Hansen HS, "Essential function of linoleic acid esterified in acylglucosylceramide and acylceramide in maintaining the epidermal water permeability barrier. Evidence from feeding studies with oleate, linoleate, arachidonate, columbinate and α-linolenate", BBA-Mol Cell Biol L, 834(3), pp.357~363 (1985)
83. Elias PM, "The permeability barrier in essential fatty acid deficiency : evidence for a direct role for linoleic acid in barrier function", J Invest Dermatol, 74(4), pp.230~233 (1980)
84. Tsuji K, "Dietary glucosylceramide improves skin barrier function in hairless mice", J Dermatol Sci, 44(2), pp.101~107 (2006)
85. Holleran WM, "Inhibition of sphingolipid synthesis delays barrier recovery after acute perturbation", J Clin Invest, 88(4), pp.1338~1345 (1991)
86. Mao-Qiang M, "Fatty acids are required for epidermal permeability barrier function", J Clin Invest, 92(2), pp.791~798 (1993)
87. Feingold KR, "Cholesterol synthesis is required for cutaneous barrier function in mice", J Clin Invest, 86(5), pp.1738~1745 (1990)
88. Nikkari T, "Isotope kinetics of human skin cholesterol secretion", J Exp Med, 141(3), pp.620~634 (1975)
89. Bhattacharyya AK, "Excretion of sterols from the skin of normal and hypercholesterolemic humans : Implications for sterol balance studies", J Clin Invest, 51(8), pp.2060~2070 (1972)
90. Grubauer G, "Relationship of epidermal lipogenesis to cutaneous barrier function", J Lipid Res, 28(6), pp.746~752 (1987)
91. Menon GK, "De novo sterologenesis in the skin. II. Regulation by cutaneous barrier requirements", J Lipid Res, 26(4), pp.418~427 (1985)
92. 송해준, "The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPI-PSODE)", Annals of Dermatology, 29(4), pp.462~470 (2017), 대한피부과학회
93. Kalantzis A, "Oral effects of low-dose methotrexate treatment", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 100(1), pp.52~62 (2005)
94. Tichy M, "Manifestation of Crohn's disease in a young woman during the course of treatment for severe form of chronic plaque psoriasis with etanercept", Dermatol Ther, 27(4), pp.211~214 (2014)
95. Guerra I, "Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease : a report of 21 cases", J Crohns Colitis, 6(5), pp.518~523 (2012)
96. Cullen G, "Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature", Aliment Pharmacol Ther, 34(11-12), pp.1318~1327 (2011)
97. Lee IW, "Saeng-Kankunbi-Tang (生肝健脾汤) protects liver against oxidative damage through activation of ERK", Nrf2 pathway, 2016, pp.22(8), 619~628
98. 김재용, "生肝健脾湯이 HepG2 cell의 증식, 세포사멸 및 활성조절 신호전달계에 미치는 영향", 대한한방내과학회지, 27(1), pp.149~165 (2006), 대한한방내과학회
99. Hong ND, "Studies on the Efficacy of the Combined Preparation of Crude Drugs (Ⅶ): Effects of Saengkankunbi-Tang on the Liver Tissue Recovery", Korean J Pharmacog, 13(2), pp.70~78 (1982)
100. Hong ND, "Studies on the Efficacy of the Combined Preparation of Crude Drugs (Ⅵ): Effect of Saengkankunbi-Tang on Activities of the Liver Enzyme, Protein Contents and the Excretory Action of Bile Juice in the Serum of CCl4-intoxicated Rabbits", Korean J Pharmacog, 13(1), pp.33~38 (1982)

관련 논문AI추천